Britain’s decision to exit the European Union will have a ‘limited’ impact on India’s pharma industry, ratings agency ICRA recently said. “The European markets account for 10–13 per cent of the total revenues with US being the largest export destination.
New Delhi/India – Accordingly, the impact of GBP and Euro depreciation is likely to be limited,” Senior VP, Co-head Corporate Sector ratings, ICRA Ltd, Subrata Ray said in a statement. However, given the fact the profitability in the European business has been low vis-a-vis other markets on account of price cuts and shift towards tender market, currency depreciation and any possibility of further austerity measures may impact the attractiveness of the market, he added.
India’s total pharma exports in 2015–16 were $13 billion. Of these, EU accounted for $1.51 billion, UK ($469 million) and the US ($5.02 billion). As for its overall exports to the EU and Britain, they stood at $35.35 billion and $9.35 billion respectively in 2015–16. They were at $40.28 billion to the US. The UK voted to leave the European Union after 43 years in a historic referendum. Leave won by 52 per cent to 48 per cent votes. The vote—which saw an extremely high turnout of around 72 per cent—reverses the public verdict back in 1975, when the UK voted to remain a member of then European Economic Community, which later became the EU.
Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.
Consent to the use of data for promotional purposes
I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here
Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.
In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.
Right of revocation
I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.